Previous 10 | Next 10 |
home / stock / abscf / abscf news
PRESS RELEASE AB SCIENCE ANNOUNCES THAT IT HAS SUBMITTED ITS RESPONSE TO THE DAY 120 QUESTIONS IN THE EMA REGULATORY REVIEW OF MASITINIB IN AMYO TROPHIC LATERAL SCLEROSIS AND CLARIFIES THE NEW TIMELINE FOR RESPONDING TO HEALTH CANADA Paris, A pril ...
PRESS RELEASE AB SCIENCE WILL HOST A LIVE WEBCAST ON ITS MICROTUBULE DESTABILIZER AGENTS (MDA) PLATFORM ON T HURSDAY MARCH 1 6 , 2023, FROM 6PM TO 7PM CET Paris, 1 5 March , 202 3 , 6pm CET AB Science SA (Eu...
PRESS RELEASE AB SCIENCE REPORTS A FIRST COMPLETE BONE MARROW RESPONSE IN A RELAPSED REFRACTORY ACUTE MYELOID LEUKEMIA ( AML ) PATIENT FROM THE VERY LOW DOSE ARM OF ITS AB8939 PHASE I/II CLINICAL TRIAL (AB18001) ...
PRESS RELEASE PUBLICATION OF THE MASITINIB PIVOTAL PHASE 3 CLINICAL TRIAL IN ALZHEIMER'S DISEASE IN THE JOURNAL ALZHEIMER'S RESEARCH & THERAPY Paris, 28 February , 202 3 , 8am CET AB Science SA (Euronext - F...
PRESS RELEASE AB SCIENCE ANNOUNCES THE DRAWDOWN OF THE SECOND TRANCHE OF 6 MILLION EUROS UNDER ITS FINANCING AGREEMENT WITH THE EUROPEAN INVESTMENT BANK Paris, January 31, 2023 , 6pm CET AB Science SA (Euronext - FR0010557264 - AB) announced today tha...
The European Medicines Agency (EMA) validated to review AB Science's ( OTC:ABSCF ) application seeking conditional approval of Alsitek (masitinib) to treat amyotrophic lateral sclerosis (ALS). The French drugmaker said that the EMA's Committee for Medicinal Products f...
Novel 3CL protease inhibitor under development. Pivot in vaccination strategy telegraphed in Fox interview. Hole in vaccination strategy creates a greater need for oral antivirals. Competition lurking but underfunded. For further details see: Pfizer's 3CL Protease In...
knowlesgallery/iStock via Getty Images The Alzheimer's Association International Conference begins Monday and runs through July 30 both in person in Denver and online. As always, there are several eagerly awaited presentations from companies working on Alzheimer's therapies that could lead to...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Satu...
Masitinib, under development from AB Science (ABSCF) for metastatic castrate-resistant prostate cancer (mCRPC), met its primary endpoint in a phase 2b/3 study.In the study, patients were randomized to masitinib and docetaxel vs docetaxel alone with the progression-free survival as the primary...
News, Short Squeeze, Breakout and More Instantly...
Ab Science Paris Ord Company Name:
ABSCF Stock Symbol:
OTCMKTS Market:
PRESS RELEASE AB SCIENCE REPORTS POSTIVE RESULTS OF ITS PHASE 2 STUDY EVALUATING MASITINIB IN COVID-19 Paris, 8 July 2024, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announces the results of a Phase 2 study evaluating masitinib in COVID-19. This rando...
PRESS RELEASE SUMMARY OF THE WEBCAST HELD ON MAY 30, 2024, PROVIDING AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, May 31, 2024, 4.30pm CET AB Science SA (Euronext - FR0010557264...
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, 29 May, 2024, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that the Commit...